60 Degrees Pharmaceuticals, Inc. — Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated January 10, 2024 and filed with a signature dated January 16, 2024, reports a Nasdaq listing compliance update. The filing does not provide a financial reporting period or operating results.
Key Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material Change Versus Prior Period
On November 2, 2023, Nasdaq notified the Company that its common stock had failed to maintain the required minimum closing bid price of $1.00 per share for 30 consecutive business days, from September 19 through November 1, 2023, under Nasdaq Listing Rule 5550(a)(2).
On January 10, 2024, Nasdaq notified the Company that its closing bid price had been at least $1.00 per share for 10 consecutive business days, from December 26, 2023 through January 9, 2024. The Company therefore regained compliance with the Bid Price Rule, and the matter was closed.
Guidance, Outlook, Risks, and Unusual Items
- The filing contains no financial guidance or business outlook.
- The principal disclosed risk was the previously reported potential Nasdaq listing deficiency related to the minimum bid price.
- That compliance matter was resolved as of January 10, 2024; the filing does not disclose additional contingencies or unusual financial items.
Important Facts for Investors to Verify
- Confirm the Company’s continued compliance with Nasdaq’s $1.00 minimum bid-price requirement after the reported compliance period.
- Review subsequent filings for any new listing notices, reverse-stock-split actions, or other capital-markets developments.
- Consult the Company’s periodic financial filings for revenue, losses, cash balances, liquidity, debt, and operating trends, which are not included in this 8-K.